Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial. | ClinicLens

The clinical efficacy and immune modulation of neoadjuvant immunochemotherapy for epithelial ovarian cancer (EOC) remain uncertain. To clarify these effects, the NAIVE trial (NCT04815408), a prospective phase II study, evaluated the efficacy of neoadjuvant platinum-based chemothe

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.